Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 20;2(5):223-234.
doi: 10.1002/jgh3.12065. eCollection 2018 Oct.

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases

Hang Hock Shim  1 , Pak Wo Chan  1 , Sai Wei Chuah  1 , Brian J Schwender  1 , San Choon Kong  1 , Khoon Lin Ling  1
Affiliations
Review

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases

Hang Hock Shim et al. JGH Open. .

Abstract

Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much-awaited out-of-class alternatives for patients who have failed or who are intolerant to anti-Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from randomized controlled trials and postmarketing cohort studies and discuss their safety, efficacy, and limitations, in relation to anti-TNF therapy, in optimizing the treatment outcomes.

Keywords: anti‐TNF; inflammatory bowel disease; ustekinumab; vedolizumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Strength of various agents in Crohn's disease (CD).
Figure 2
Figure 2
Strength of various agents in ulcerative colitis (UC).
See this image and copyright information in PMC

References

    1. Bouguen G, Peyrin‐Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut. 2011; 60: 1178–81. 10.1136/gut.2010.234617. - DOI - PubMed
    1. Targan S, Hanauer S, van Deventer S et al A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N. Engl. J. Med. 1997; 337: 1029–35. - PubMed
    1. Khanna R, Bressler B, Levesque BG et al Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015; 386: 1825–34. 10.1016/S0140-6736(15)00068-9. - DOI - PubMed
    1. Khanna R, Sattin BD, Afif W et al Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013; 38: 447–59. 10.1111/apt.12407. - DOI - PubMed
    1. Sandborn WJ, Feagan BG, Rutgeerts P et al Vedolizumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2013; 369: 711–21. 10.1056/NEJMoa1215739. - DOI - PubMed